Authors
Latest:
Impact of Regorafenib and Sorafenib in the Treatment of Liver CancerDr. Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses the major impact that regorafenib and sorafenib will have for the treatment of liver cancer.
Latest:
Comparing Bosutinib Versus Imatinib in Newly Diagnosed CMLJorge Cortes, MD, deputy chair of the Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses initial results from the BFORE trial, which is exploring bosutinib (Bosulif) versus imatinib (Gleevec) for newly diagnosed chronic myeloid leukemia.
Latest:
Safety of Olutasidenib in IDH1-Mutated R/R AMLJorge E. Cortes, MD, discusses the safety profile of olutasidenib for the treatment of patients with relapsed/refractory acute myeloid leukemia that harbor an IDH1 mutation.
Latest:
Using Biology to Determine Type and Duration of Treatment in Waldenström MacroglobulinemiaJorge J. Castillo, MD, will explore the challenges of managing WM. He will present on September 30, 2022, at 11:04 AM.
Latest:
Comparing Frontline Therapies for the Treatment of Chronic Myeloid LeukemiaJorge E. Cortes, MD, discusses the frontline treatment options for patients with chronic myeloid leukemia.
Latest:
Dr. Jose P. Zevallos on Molecular Testing for Smokers With HPV+ Oropharyngeal SCCZevallos says that while HPV-positive oropharyngeal SCC has a positive outcome for patients, smoking status should be taken into account for these patients when making a decision to deintensify therapy.
Latest:
Recent Advancements for the Treatment of Liver CancerJosep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program and professor of medicine at the Icahn School of Medicine, Mount Sinai Hospital, discusses the current treatment landscape for liver cancer and the advances seen over the last decade at the 2018 International Liver Cancer Association Annual Conference.
Latest:
New Agents Shake Up Treatment Landscape for Patients With HCCJosep M. Llovet, MD, PhD, discusses the evolution of treatment options for patients with hepatocellular carcinoma.
Latest:
Prolonging Responses in Locally Advanced Breast CancerJoseph A. Sparano, MD, who recently gave a talk during the 19th Annual School of Breast Oncology, discusses prolonging responses to therapy in patients with advanced breast cancer.
Latest:
Treating HIV-Associated LymphomaJoseph Alvarnas, MD, Director of Medical Quality, associate clinical professor, City of Hope, discusses the treatment of HIV-associated lymphoma.
Latest:
Microsatellite Instability Serves as a Predictive Biomarker of Response to PembrolizumabJoseph Chao, MD, discusses the importance of assessing the microsatellite instability (MSI) status in patients with advanced gastric/gastroesophageal junction cancer based on findings from a comparative analysis of KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062.
Latest:
Adjusting Dosing to Increase Efficacy of Cetuximab in Head and Neck CancerJoseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses how dosing adjustments may be used to increase the efficacy of agents, such as cetuximab (Erbitux) in patients with head and neck cancer.
Latest:
Abiraterone With Low-Dose Prednisone in Patients With Prostate CancerJoseph F. Renzulli, II, MD, FACS, assistant professor of Surgery, (Urology), Alpert Medical School, Brown University, discusses a phase II study that examined the use of abiraterone acetate with low-dose prednisone in patients with prostate cancer.
Latest:
Radioimmunotherapy as Treatment for AMLJoseph Jurcic, MD, head, Hematologic Malignancies, Columbia University Medical Center, discusses using radioimmunotherapy as a treatment option for patients with AML.
Latest:
Results of the Phase II GAGE Trial in CLLJoseph M. Flynn, DO, MPH, co-director, Division of Hematology; co-director, LIVESTRONG Survivorship Center of Excellence; medical director, James Survivorship Clinics, The Ohio State University, James Cancer Hospital, discusses the results of the phase II GAGE study, which compared 1000 mg vs 2000 mg of obinutuzumab in patients with chronic lymphocytic leukemia (CLL).
Latest:
Oligometastatic Disease in Cancer: Broadening the Path to Cure?Emerging data indicate that patients with metastasis to a limited number of sites may have improved outcomes with the use of locally ablative therapy. The availability of minimally invasive LAT has led to the widespread adoption of this practice for patients with oligometastatic disease. There are currently no clear predictors of improved survival after LAT across tumor subtypes. New data suggest the use of molecular biomarkers and combination therapies improve patient outcomes.
Latest:
Discussing the Evolution of Immunotherapy in LymphomasJoshua Brody, MD, discusses how he sees the use of immunotherapy evolving in coming years.
Latest:
Second-line and Beyond: Treatment of ALK+ mNSCLCManaging patients with who progress on a TKI, the role of re-biopsy at progression of disease, and the future treatment landscape for ALK+ mNSCLC.
Latest:
Examining Self-Reported Symptoms in Patients With Multiple MyelomaJoshua R. Richter, MD, a hematologist/oncologist at John Theurer Cancer Center, discusses results from the Living with Cancer patient-reported outcomes (PROs) tool, which is a survey to record self-reported symptoms from patients. Richter used this tool to survey 239 patients with multiple myeloma on their symptoms and psychological distress.
Latest:
Challenges with Diversity in Clinical TrialsJoshua Richter, MD, talks about the barriers to diversity in oncology clinical trials.
Latest:
Case 3: Role of Preoperative Endocrine Therapy in HR+ High-Risk Breast CancerHeather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’Shaughnessy, MD, comment on the role of preoperative endocrine therapy in HR-positive high-risk breast cancer.
Latest:
Expert Discusses Promise of Abemaciclib for Breast Cancer TreatmentJoyce A. O’Shaughnessy, MD, chair of Breast Cancer Research and the Celebrating Women Chair in Breast Cancer at Baylor-Sammons Cancer Center, discusses the promise seen with abemaciclib for the treatment of breast cancer.
Latest:
Evaluating the Impact of Elacestrant Use in Clinical Practice for Patients With ER+/HER2-Metastasized Breast CancerIdentifying the impact of elacestrant in clinical practice for patients with ER+/HER2- metastatic breast cancer.
